Adastra Pharmaceuticals
Founded Year
2005Stage
Series E - II | AliveTotal Raised
$90.65MLast Raised
$1.4M | 3 yrs agoAbout Adastra Pharmaceuticals
Adastra Pharmaceuticals is a private, clinical-stage biopharmaceutical company committed to providing responsible solutions to advance patient care in oncology. Its vision is to identify, develop, and deliver to patients important new therapies for diseases with significant unmet needs. This commitment is epitomized by its lead clinical candidate, zotiraciclib, which is initially being developed for the treatment of high-grade gliomas (HGG) and diffuse intrinsic pontine glioma (DIPG), two forms of brain cancer characterized by Myc overexpression. Adastra possesses a rich history of institutional and academic collaboration, including ongoing clinical research programs with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC).
Missing: Adastra Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Adastra Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Adastra Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Adastra Pharmaceuticals is included in 2 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Adastra Pharmaceuticals Patents
Adastra Pharmaceuticals has filed 4 patents.
The 3 most popular patent topics include:
- Experimental cancer drugs
- Transcription factors
- Acute myeloid leukemia
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/12/2020 | 11/16/2021 | Transcription factors, Brain tumor, Oncology, Radiation therapy, Experimental cancer drugs | Grant |
Application Date | 8/12/2020 |
|---|---|
Grant Date | 11/16/2021 |
Title | |
Related Topics | Transcription factors, Brain tumor, Oncology, Radiation therapy, Experimental cancer drugs |
Status | Grant |
Latest Adastra Pharmaceuticals News
Oct 6, 2021
Cothera to Advance Clinical Development of Oral Kinase Inhibitor with Unique Myc Depletion I want to thank all the physicians and dedicated healthcare providers who have put forward relentless effort on behalf of their patients as the Adastra team transitions zotiraciclib into Cothera.” — Scott Megaffin, Chief Executive Officer, Adastra PRINCETON, NEW JERSEY, USA, October … Continue reading "Cothera Bioscience Acquires Zotiraciclib from Adastra Pharmaceuticals"
Adastra Pharmaceuticals Frequently Asked Questions (FAQ)
When was Adastra Pharmaceuticals founded?
Adastra Pharmaceuticals was founded in 2005.
Where is Adastra Pharmaceuticals's headquarters?
Adastra Pharmaceuticals's headquarters is located at 202 Carnegie Center, Princeton.
What is Adastra Pharmaceuticals's latest funding round?
Adastra Pharmaceuticals's latest funding round is Series E - II.
How much did Adastra Pharmaceuticals raise?
Adastra Pharmaceuticals raised a total of $90.65M.
Who are the investors of Adastra Pharmaceuticals?
Investors of Adastra Pharmaceuticals include Domain Associates, ProQuest Investments, Mitsubishi Corporation, Rusnano, Morgenthaler Ventures and 7 more.
Who are Adastra Pharmaceuticals's competitors?
Competitors of Adastra Pharmaceuticals include Viracta Therapeutics, Bexion Pharmaceuticals, Vaccinex, Solasia Pharma, Kolltan Pharmaceuticals, Reata Pharmaceuticals, Alligator Bioscience, Nps Pharmaceuticals, Questcor Pharmaceuticals, Acton Pharmaceuticals and 13 more.
Compare Adastra Pharmaceuticals to Competitors
Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.
P2D, Inc. is a pharmaceutical company focused on developing new pharmaceuticals for brain disorders
IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.
Kanisa Pharmaceuticals is a pharmaceutical company focused on the acquisition, development and commercialization of therapeutics in the field of oncology.
Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the healthcare community with relevant products and services that directly benefit those affected by neurological disorders. In the first half of 2010, Nautilus intends to launch a novel product, CAMBIA¯¿½ (diclofenac potassium for oral solution).
VGXI is a contract manufacturer of plasmid DNA. The company delivers flexibility, experience, reliability, and value to clients’ challenging programs. The company’s cGMP and non-cGMP products have passed rigorous international regulatory reviews.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.